Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 4/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237129 | 0.84 | ATM (0.38) | ATMTRIM24TRIM33HDAC8TDP1 | |
| SCHEMBL21727606 | 0.77 | ALDH1A1 (0.37) | ATMBRD4 | |
| SCHEMBL3465365 | 0.72 | TDP1 (0.33) | HDAC8BRD4TDP1 | |
| SCHEMBL2072144 | 0.71 | HDAC8 (0.58) | ATMTRIM24TRIM33HDAC8 | |
| SCHEMBL16271028 | 0.71 | — | — | |
| SCHEMBL22342725 | 0.70 | — | — | |
| SCHEMBL5393454 | 0.70 | — | — | |
| SCHEMBL7041627 | 0.70 | G6PD (0.38) | BRD4ENPP2PTGS2TDP1 | |
| SCHEMBL2072141 | 0.67 | ATM (0.40) | ATMTRIM24TRIM33HDAC8 | |
| SCHEMBL5400147 | 0.67 | ATM (0.40) | ATMTRIM24TRIM33HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| US-7432267-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMAPNY (US) | 2008-10-07 | — | — | US | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | disclosed |
| EP-1664052-A1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| US-7001911-B2 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2005016929-A1 | FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1463728-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-22 | — | — | US | disclosed |
| WO-2003053354-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-06-19 | — | — | US | disclosed |
| EP-1299385-A2 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002000653-A2 | FUSED CYCLIC COMPOUNDS AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | ATM 3669/4885TRIM24 3775/4885TRIM33 4228/4885 |
| US-20030114420-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ATM 1835/4885TRIM24 839/4885TRIM33 2374/4885 |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | GLUL, RIMKLA, GGH | ATM 4631/4885TRIM24 2599/4885TRIM33 2684/4885 |
| US-20040077606-A1 | Fused cyclic modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR3C1 | ATM 1835/4885TRIM24 839/4885TRIM33 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.